Lupin: Company Approves Mr. Anand Kripalu's Appointment As Additional Non-Executive Independent Director Starting On February 01

 06 Jan 2026 09:22 PM

Lupin: Company Approves Mr. Anand Kripalu's Appointment As Additional Non-Executive Independent Director Starting On February 01

Lupin: Company Signs Exclusive Licensing Deal With Gan & Lee Pharmaceuticals For New GLP-1 Receptor Agonis

 29 Dec 2025 06:28 PM

Lupin: Company Signs Exclusive Licensing Deal With Gan & Lee Pharmaceuticals For New GLP-1 Receptor Agonis

Lupin: Company Partners With Neopharmed For Exclusive Licensing Of Gastroenterology Drug Plasil In Philippines And Brazil

 18 Dec 2025 05:04 PM

Lupin: Company Partners With Neopharmed For Exclusive Licensing Of Gastroenterology Drug Plasil In Philippines And Brazil

Lupin Limited: Gets Favorable Opinion From CHMP For Biosimilar Ranibizumab; Marketing Approval Suggested For Vial And Pre-Filled Syringe Forms; Sandoz Group AG To Manage Marketing In EU

 17 Dec 2025 11:50 AM

Lupin Limited: Gets Favorable Opinion From CHMP For Biosimilar Ranibizumab; Marketing Approval Suggested For Vial And Pre-Filled Syringe Forms; Sandoz Group AG To Manage Marketing In EU

Lupin: Company Gets EIR Approval From US FDA For Nagpur Injectable Plant

 16 Dec 2025 08:54 PM

Lupin: Company Gets EIR Approval From US FDA For Nagpur Injectable Plant

Lupin: Co Manufacturing Solutions Partners With Polypeptide To Expand Global Peptide Supply Chain

 12 Dec 2025 11:46 AM

Lupin: Co Manufacturing Solutions Partners With Polypeptide To Expand Global Peptide Supply Chain

Lupin: Company Gets Tentative Approval From U.S. FDA For Siponimod Tablets, Market Potential Estimated At $200 Million

 05 Dec 2025 09:27 AM

Lupin: Company Gets Tentative Approval From U.S. FDA For Siponimod Tablets, Market Potential Estimated At $200 Million

Lupin: Company Partners with Valorum for Exclusive Licensing Deal of Biosimilar Armlupeg in the U.S.

 04 Dec 2025 01:18 PM

Lupin: Company Partners with Valorum for Exclusive Licensing Deal of Biosimilar Armlupeg in the U.S.

Lupin: CITI on Lupin Buy, Price Target Rs 2260

 01 Dec 2025 09:10 AM

Lupin: CITI on Lupin Buy, Price Target Rs 2260

Lupin: Company And Several PE Firms, Including TPG And EQT, Are In Talks To Buy UK's Biggest Nutraceutical Firm Vitabiotics -ET

 01 Dec 2025 08:41 AM

Lupin: Company And Several PE Firms, Including TPG And EQT, Are In Talks To Buy UK's Biggest Nutraceutical Firm Vitabiotics -ET

Lupin: Company, TPG Capital, and EQT are Negotiating to Purchase Family-Owned Vitabiotics. - ET

 01 Dec 2025 08:23 AM

Lupin: Company, TPG Capital, and EQT are Negotiating to Purchase Family-Owned Vitabiotics. - ET

Lupin: Company Gains U.S. FDA Approval For Biosimilar Armlupeg (Pegfilgrastim-Unne) With Estimated Annual Sales Of $1.295 Billion In The U.S.

 01 Dec 2025 07:58 AM

Lupin: Company Gains U.S. FDA Approval For Biosimilar Armlupeg (Pegfilgrastim-Unne) With Estimated Annual Sales Of $1.295 Billion In The U.S.

Lupin: Jefferies on Lupin Buy, target price Rs 2300

 25 Nov 2025 09:02 AM

Lupin: Jefferies on Lupin Buy, target price Rs 2300

Lupin: Company Confirms FDA Inspection Closure Of Nagpur Unit-1 With No Issues Found

 15 Nov 2025 07:14 PM

Lupin: Company Confirms FDA Inspection Closure Of Nagpur Unit-1 With No Issues Found

Lupin: Unveils Risperidone Long-Acting Injectable With 180-Day CGT Exclusivity In The U.S., Marking The First Launch From Its PrecisionSphere Platform.

 14 Nov 2025 08:23 AM

Lupin: Unveils Risperidone Long-Acting Injectable With 180-Day CGT Exclusivity In The U.S., Marking The First Launch From Its PrecisionSphere Platform.

Lupin: Company Gets EIR From U.S. FDA For Aurangabad Facility

 13 Nov 2025 08:18 AM

Lupin: Company Gets EIR From U.S. FDA For Aurangabad Facility

Lupin: Plans To Release Risperdal Consta Soon And Recently Introduced A Generic Version Of Ravicti - Concall Update

 10 Nov 2025 09:14 AM

Lupin: Plans To Release Risperdal Consta Soon And Recently Introduced A Generic Version Of Ravicti - Concall Update

Lupin: Full Year FY26 EBITDA Margins Projected at 25-26%, Up from Previous Estimate of 24-25% || FY27 EBITDA Margins Expected to Stay at 24-25% - Conference Call Update

 10 Nov 2025 09:09 AM

Lupin: Full Year FY26 EBITDA Margins Projected at 25-26%, Up from Previous Estimate of 24-25% || FY27 EBITDA Margins Expected to Stay at 24-25% - Conference Call Update

Lupin: Full Year FY26 Tax Rate Anticipated Between 21-22% 💰 || Company Aims for 5 Biosimilar Products in Market by FY30, Expects to Outperform IPM by 1.2X to 1.3X for India Formulations Business - Concalls Update

 10 Nov 2025 09:12 AM

Lupin: Full Year FY26 Tax Rate Anticipated Between 21-22% 💰 || Company Aims for 5 Biosimilar Products in Market by FY30, Expects to Outperform IPM by 1.2X to 1.3X for India Formulations Business - Concalls Update

Lupin: Company Aims to Introduce 80+ New Products in India Soon, Starting with Semaglutide Launches - Concall Update

 10 Nov 2025 09:14 AM

Lupin: Company Aims to Introduce 80+ New Products in India Soon, Starting with Semaglutide Launches - Concall Update